Share |
Board of Directors

Karen Boodram

B.Sc., MBA

Karen Boodram comes to us from PI Financial Corp. where she served as a Life Sciences Analyst and has over 18 years of life sciences industry experience including Director of External Affairs for Novartis Pharmaceuticals and several senior management positions (including Manager of Health Economics) for Ciba-Geigy Pharmaceuticals, spanning both the Canadian and European marketplace. Prior to joining PI Financial Corp., Karen led BioManna Consulting where she spearheaded and managed projects for the National Research Council as well as biotechnology, pharmaceutical and medical device companies in North America. Karen is a graduate of the University of Alberta with Bachelor of Science Degrees in Biochemistry and Pharmacy as well as an MBA. She is also a member of the Alberta Pharmaceutical Association.

Thomas Braun


Prior to founding the company, Thomas Braun practiced corporate securities law, specializing in representing small high tech public companies. Mr. Braun is experienced in the management of public companies and has conducted dozens of mergers and acquisitions and going public transactions.

Mr. Braun earned a BA degree from the University of Western Ontario, a Juris Doctor (JD) degree from the University of British Columbia, and a Master of Laws (LLM) degree from the University of San Francisco specializing in International Business Transactions. He is a member of the State Bar of California, and is also a member of the Law Society of British Columbia. He is also admitted to practice before the Federal Court for the Northern District of California and the Ninth Circuit Court Appeals.

Dr. Jake Thiessen


Dr. Jake J. Thiessen is the Hallman Director, School of Pharmacy, and Director, Health Sciences Campus, University of Waterloo. Jake is a former professor and associate dean at the Leslie Dan Faculty of Pharmacy, University of Toronto. He earned his B.Sc. (Pharm) degree from the University of Manitoba, and went on to complete a M.Sc. at Manitoba and a Ph.D. at the University of California, San Francisco. Jake's area of specialization is pharmacokinetics. His research interests include new approaches in cancer treatment and new molecules to treat patients with iron overload. He has broadened his experience and shared his expertise through work with the Drug Quality and Therapeutics Committee of the Ontario Ministry of Health, Health Canada's Scientific Advisory Committee on Bioavailability and Bioequivalence, and the Canadian Council for Accreditation of Pharmacy Programs.

  Back to top